Results 11 to 20 of about 10,088 (191)

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies

open access: yesCells, 2022
Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota.
Lung Chan, Yun-Ru Liu, Hsun-Hua Lee
exaly   +4 more sources

Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?

open access: yesАнтибиотики и Химиотерапия, 2020
Rifaximin is an antibiotic characterized by polymorphism. It has various crystalline forms with different pharmacological characteristics. Rifaximin acts locally in the digestive tract, therefore it is important for the absorption to be minimal and for ...
S. K. Zyryanov, E. A. Baybulatova
doaj   +2 more sources

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome [PDF]

open access: yesClinical and Experimental Gastroenterology, 2011
John JolleyDepartment of Medicine, University of California, San Francisco, CA, USABackground: To evaluate the efficacy of rifaximin for reduction of gastrointestinal symptoms in patients with irritable bowel syndrome (IBS).Methods: Medical records were ...
Jolley J
doaj   +2 more sources

Beyond Prophylaxis: Antimicrobial Stewardship for Bacterial Infections in Cirrhosis. [PDF]

open access: yesUnited European Gastroenterol J
United European Gastroenterology Journal, Volume 14, Issue 9, November 2026.
Haedge F, Mücke MM, Lange CM, Bruns T.
europepmc   +2 more sources

Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial

open access: yesScientific Reports
Rifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC)
Gabriela Leite   +12 more
doaj   +2 more sources

The Pros & Cons of Measuring Plasma Ammonia in the Management of Patients With Cirrhosis: An ISHEN Debate [PDF]

open access: yesLiver Int
ABSTRACT Ammonia is a nitrogenous molecule which is primarily generated in the gastrointestinal tract. The neurotoxicity of ammonia plays a critical role in the liver's regulation of circulating ammonia levels. In liver disease, an increase in blood ammonia has been long implicated in the pathogenesis of hepatic encephalopathy (HE), a neurological ...
Ballester M, Bloom P, Rose C.
europepmc   +2 more sources

The Use of Rifaximin in Patients With Cirrhosis [PDF]

open access: yesHepatology, 2021
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical
Caraceni, Paolo   +46 more
core   +8 more sources

Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy. [PDF]

open access: yesGut Microbes
Chemotherapy-induced intestinal mucositis is a frequent and dose-limiting toxicity that compromises cancer treatment outcomes and lacks effective targeted interventions.
Correale C   +16 more
europepmc   +2 more sources

Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort. [PDF]

open access: yesClin Mol Hepatol
Background/Aims Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting ...
Bajaj JS   +14 more
europepmc   +2 more sources

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

open access: yesFrontiers in Pharmacology, 2022
Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy ...
Jie Jian   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy